BR112017009315A2 - composição de pó seco farmacêutico inalável, processo para preparar uma composição de pó seco farmacêutico inalável, e, método para tratar transtornos respiratórios. - Google Patents

composição de pó seco farmacêutico inalável, processo para preparar uma composição de pó seco farmacêutico inalável, e, método para tratar transtornos respiratórios.

Info

Publication number
BR112017009315A2
BR112017009315A2 BR112017009315A BR112017009315A BR112017009315A2 BR 112017009315 A2 BR112017009315 A2 BR 112017009315A2 BR 112017009315 A BR112017009315 A BR 112017009315A BR 112017009315 A BR112017009315 A BR 112017009315A BR 112017009315 A2 BR112017009315 A2 BR 112017009315A2
Authority
BR
Brazil
Prior art keywords
dry powder
powder composition
inhalable pharmaceutical
pharmaceutical dry
preparing
Prior art date
Application number
BR112017009315A
Other languages
English (en)
Inventor
Jadhav Ganesh
Trivedi Girish
Chaudhari Sunil
Dhuppad Ulhas
Original Assignee
Glenmark Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Ltd filed Critical Glenmark Pharmaceuticals Ltd
Publication of BR112017009315A2 publication Critical patent/BR112017009315A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

é provida uma composição farmacêutica inalável compreendendo glicopirrônio ou seu sal. preferivelmente, é provida uma composição farmacêutica inalável compreendendo uma quantidade efetiva de glicopirrônio ou seu sal e lactose; um processo para preparar tal composição e seu uso no tratamento de transtornos respiratórios.
BR112017009315A 2014-11-05 2015-11-05 composição de pó seco farmacêutico inalável, processo para preparar uma composição de pó seco farmacêutico inalável, e, método para tratar transtornos respiratórios. BR112017009315A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3493MU2014 2014-11-05
PCT/IB2015/058550 WO2016071862A1 (en) 2014-11-05 2015-11-05 Inhalable pharmaceutical composition comprising glycopyrronium

Publications (1)

Publication Number Publication Date
BR112017009315A2 true BR112017009315A2 (pt) 2017-12-19

Family

ID=55908675

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017009315A BR112017009315A2 (pt) 2014-11-05 2015-11-05 composição de pó seco farmacêutico inalável, processo para preparar uma composição de pó seco farmacêutico inalável, e, método para tratar transtornos respiratórios.

Country Status (2)

Country Link
BR (1) BR112017009315A2 (pt)
WO (1) WO2016071862A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT109445B (pt) * 2016-06-08 2018-11-06 Hovione Farm Sa Co-cristais farmacêuticos cristalinos de brometo de glicopirrónio com lactose
WO2019060595A1 (en) * 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM
WO2019060604A1 (en) * 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE MEDICINE

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0525254D0 (en) * 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
JO3510B1 (ar) * 2011-03-04 2020-07-05 Heptares Therapeutics Ltd استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب
TR201205852A2 (tr) * 2011-06-02 2012-12-21 Bi̇lgi̇ç Mahmut Geliştirilmiş yeni kuru toz formülasyonu.

Also Published As

Publication number Publication date
WO2016071862A1 (en) 2016-05-12

Similar Documents

Publication Publication Date Title
PH12017501046A1 (en) Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases
CL2016001715A1 (es) Nuevos inhibidores de glutaminasa
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
EP4282479A3 (en) Use of pridopidine to treat depression or anxiety
BR112017001789A2 (pt) composições e métodos de uso para tratamento de distúrbios metabólicos
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
HK1252813A1 (zh) 用於治療社交障礙和藥物使用障礙的治療性化合物和組合物
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
EA201991175A1 (ru) Применение в медицине интерферона-лямбда для лечения фиброза
AR100369A1 (es) Composición de dosis fija de formoterol y budesonide
PH12016502530A1 (en) Pharmaceutical compositions comprising dgla and use of same
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
HK1257588A1 (zh) 預防和治療肺纖維化的藥物及其用途
BR112018009745A2 (pt) compostos heterocíclicos para o tratamento de doença
ES2970546T3 (es) Compuestos, procedimiento para obtener los compuestos, composición farmacéutica, uso de los compuestos y método para tratar trastornos psiquiátricos y/o trastornos del sueño
BR112017009315A2 (pt) composição de pó seco farmacêutico inalável, processo para preparar uma composição de pó seco farmacêutico inalável, e, método para tratar transtornos respiratórios.
ZA201802680B (en) Process and preparation of compounds for use in the treatment of androgen deprivation therapy associated symptoms
IL260068B (en) Cinnamamide history is being converted to use in anti-anxiety therapy
BR112019003133A2 (pt) agonista de ppargama para o tratamento de distúrbios ósseos
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
BR112016025244A2 (pt) uso de ácido 1,3-propanodissulfônico ou sais farmaceuticamente aceitáveis dos mesmos para o tratamento de sarcoidose.
EA202091618A1 (ru) Композиция кетамина в виде сухого порошка для применения при лечении депрессии ингаляционным путем
PH12016502107A1 (en) Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
BR112017021589A2 (pt) métodos para o tratamento de transtornos cardiovasculares
TR201604127A2 (en) Use of composition that contains local anesthetic for treating nausea

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B04C Request for examination: application reinstated [chapter 4.3 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]